SERM2

SERM2 is a novel selective estrogen receptor modulator (SERM) developed by Forendo Pharma. It is characterized by high binding affinity for estrogen receptor alpha (ERα), estrogen receptor beta (ERβ), and the progesterone receptor (PGR). Mechanistically, SERM2 promotes the production of anti-inflammatory cytokines, specifically interleukin-10 (IL-10) and interleukin-4 (IL-4), and induces the polarization of macrophages toward an anti-inflammatory M2 phenotype. Preclinical studies in murine models of dextran sodium sulfate (DSS)-induced colitis indicate that SERM2 significantly reduces disease activity, prevents mucosal erosion, and alleviates clinical symptoms of ulcerative colitis by restoring gut homeostasis and enhancing M2-like monocyte flux to sites of inflammation.